Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ukrainian Firm To Receive mRNA Tech Transfer From WHO Hub

Executive Summary

The Ukrainian pharma firm Darnitsa, which is the latest firm to benefit from the WHO’s mRNA coronavirus vaccine initiative, says it is continuing production amidst the continuing Russian attacks on the country. Meanwhile, the European Medicines Agency has issued guidance for sponsors on methodological aspects of trials affected by the war.

You may also be interested in...

WHO Inaugurates South African mRNA Technology Hub

More than 200 people took part in a meeting to assess progress with an mRNA technology transfer program that is intended to give manufacturers in lower-income countries the ability to produce and sell their own vaccines for COVID-19 and other diseases.

How To Transfer Clinical Trial Participants From Ukraine To EU Sites

An EU expert group and a number of member state agencies have published advice on the practicalities of safely moving Ukrainian clinical trial subjects to sites in EU and European Economic Area countries.

Coronavirus Notebook: Six African Countries To Produce mRNA Vaccines, CEPI Funds Indian Candidates

Alvea, a US biotech startup, says its first two DNA vaccine candidates are undergoing “rigorous” preclinical testing and could enter clinical trials as early as April this year.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts